Sharemaestro Newsreel

Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Levi & Korsinsky LLP has announced a class action securities lawsuit against Merck & Co., Inc. (NYSE:MRK) for shareholders who suffered losses due to alleged securities fraud between February 3, 2022, and February 3, 2025. The lawsuit claims Merck misrepresented expected Gardasil sales, leading …

AbbVie Inc. 2026: Revenue $16.99B, EPS $2.03— 10-Q Summary

AbbVie Inc. reported its 2026 quarterly results, with revenue reaching $16.99 billion and diluted EPS at $2.03, marking significant growth over the prior year. This performance was attributed to strong sales of key brands like Skyrizi, Rinvoq, and neuroscience products, despite a decline in …

Form 144 BIOGEN INC. For: 3 August By Investing.com

This article from Investing.com is a brief announcement regarding a Form 144 filing for BIOGEN INC. on August 3rd. It provides no further details about the filing, serving primarily as a notification of its existence. The article also includes various market data, news headlines, …

FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto

The FDA has approved Novartis' Pluvicto for an earlier stage of metastatic hormone-sensitive prostate cancer, significantly expanding the eligible patient population. This approval is based on the Phase 3 PSMAddition study, which showed a substantial reduction in disease progression or death when Pluvicto was …

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

Eli Lilly and Company announced that the U.S. FDA has granted Breakthrough Therapy designation to olomorasib as a monotherapy for treating advanced pancreatic cancer in adults with a KRAS G12C mutation who have undergone at least one prior systemic therapy. This designation aims to …

Amgen contends with data breach, exposing patient information

Amgen has experienced a data breach affecting its third-party cloud-based systems, compromising both company-owned data and private patient health information. The company has initiated its cybersecurity response plan and believes the incident is "not reasonably likely" to materially impact its financial condition or operations. …

California's highest court rules for Gilead in 'duty to innovate' case

California's highest court has sided with Gilead Sciences in a landmark "duty to innovate" case, dismissing negligence claims from 24,000 HIV patients. The court ruled that drug manufacturers are not liable for failing to make a different, potentially safer drug available sooner, even if …

Amgen (AMGN) Discloses Material Cybersecurity Incident Involving Data Exfiltration

Amgen (AMGN) has disclosed a material cybersecurity incident involving unauthorized access to data in third-party cloud environments, resulting in the exfiltration of proprietary data, patient protected health information, and other sensitive information. While the investigation is ongoing, Amgen does not currently believe the incident …

BIOGEN INC. SEC Filing (Aug 3, 2026)

This SEC filing for Biogen Inc. (BIIB) is a Form 144, indicating a proposed sale of securities under Rule 144. The filing, dated August 3, 2026, details a restricted stock vesting for 593 shares of common stock, with an aggregate market value of $120,580.62, …

Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone

Jim Cramer highlighted Johnson & Johnson's FDA approval of its OTTAVA Robotic Surgical System as a critical factor in shifting market sentiment, finally recognizing the company as a high-tech innovator. He had been advocating for J&J as a "permit stock" to balance portfolios against …

Grifols, S.A. (0RDU.L) Stock Price, News, Quote & History

This Yahoo Finance page provides detailed financial information for Grifols, S.A. (0RDU.L), including its current stock price, historical data, key statistics, performance overview, and financial highlights. It describes Grifols as a company involved in the research, development, production, and marketing of plasma-derived medicines and …

GSK plc (GSK) reports 4,045,411,246 voting rights as of July 2026

GSK plc has reported its total voting rights as 4,045,411,246 as of July 31, 2026, in accordance with the Financial Conduct Authority's disclosure requirements. The company's issued share capital included 4,316,292,310 Ordinary Shares, with 270,881,064 of these held in Treasury, which do not carry …

Canaccord raises Abbvie stock price target to $290 on Q2 beat

Canaccord Genuity increased its price target for Abbvie Inc. (NYSE:ABBV) to $290 from $282, maintaining a Buy rating, following the company's strong second-quarter performance. Abbvie exceeded revenue and earnings expectations, particularly in its Immunology and Neuroscience franchises, leading to a raised 2026 revenue guidance. …

AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter

Morningstar is maintaining its $200 fair value estimate for wide-moat AbbVie following a strong second quarter, which saw 10.2% top-line growth and 22.9% adjusted diluted EPS growth. The company's immunology portfolio, particularly Skyrizi and Rinvoq, continues to drive strong double-digit growth, despite increasing competition. …

AmGen Announces Cyberattack and Data Breach Involving Patient Data

Amgen Inc. has disclosed a cybersecurity incident where unauthorized actors accessed third-party cloud storage systems, exfiltrating proprietary data and patients’ protected health information. The biopharmaceutical company reported the material incident to the SEC, initiated an investigation with digital forensics experts, and is currently assessing …

Merck & Co., Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

Levi & Korsinsky, LLP has filed a class action securities lawsuit against Merck & Co., Inc. (NYSE:MRK) on behalf of shareholders who suffered losses due to alleged securities fraud between February 3, 2022, and February 3, 2025. The lawsuit claims Merck misrepresented its projected …

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

The article argues that a potential merger between AstraZeneca and Bristol Myers Squibb, valued at nearly $400 billion, would be a disaster. It highlights severe regulatory concerns due to significant portfolio overlaps, potential pipeline disruptions, and massive job losses as key reasons against such …

AstraZeneca slides Monday, underperforms market

AstraZeneca PLC (AZN) shares fell by 8.96% to £115.00 on Monday, underperforming the broader market as the FTSE 100 Index also saw a slight decline. This drop left AstraZeneca's stock 26.90% below its 52-week high achieved in February.

Kaléo Announces License Agreement with Amgen for Auto-Injector Technology

Kaléo announced a confidential license agreement with Amgen Inc., granting Amgen access to Kaléo's patented auto-injector technology. This agreement highlights Kaléo's leadership in drug-device technologies and patient-centric auto-injector solutions, though the financial terms were not disclosed. Kaléo specializes in drug-delivery device technology and auto-injector …

Novo’s late-stage IL-6 stumble shakes inflammation space

Novo Nordisk's investigational IL-6 inhibitor ziltivekimab failed to meet its primary endpoint in the Phase 3 ZEUS trial, which aimed to improve cardiovascular outcomes. This failure has significantly impacted other companies developing drugs targeting inflammation, particularly BioAge Labs and Monte Rosa Therapeutics, whose stock …

GSK India first-quarter profit rises on steady vaccine demand

GlaxoSmithKline Pharmaceuticals (GSK India) reported a 15.7% increase in first-quarter profit, driven by stable demand for its vaccine and drug portfolio. The company's revenue from operations rose by 16.6%, and it plans to launch new treatments, including Blenrep for multiple myeloma and the Arexvy …

Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

Citi maintains a 'neutral' rating on Novo Nordisk (NYSE:NVO), believing the market's reaction to a failed heart drug trial (ziltevekimab) is excessive given its minor contribution to the company's valuation. However, ongoing concerns about pricing pressure and increasing competition in the GLP-1 obesity drug …

Grifols, S.A. (GRFS) Stock Analysis: Exploring Its 38% Potential Upside in the Healthcare Sector

Grifols, S.A. (GRFS) is highlighted as a compelling investment opportunity in the healthcare sector, with a potential upside of 38.06%. Despite a recent stock dip, the company's strong free cash flow, sustainable dividend, and diverse product offerings position it for growth. Analysts have issued …

3,522 Shares in Amgen Inc. $AMGN Bought by VectorGlobal IAG Inc.

VectorGlobal IAG Inc. recently acquired 3,522 shares of Amgen Inc. (NASDAQ:AMGN) worth approximately $1.24 million, making it a new stakeholder in the biotechnology company. Institutional investors collectively own 76.5% of Amgen's stock, which has seen positive news like an expanded European recommendation for Repatha …

Segall Bryant & Hamill LLC Buys Shares of 23,026 Amgen Inc. $AMGN

Segall Bryant & Hamill LLC has acquired 23,026 shares of Amgen Inc., valued at approximately $8.7 million, marking a new position for the institutional investor. Amgen exceeded its Q1 earnings expectations, reporting $5.15 EPS against an $8.62 billion revenue, and declared a quarterly dividend …

AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks (XLV:NYSEARCA)

AstraZeneca leads pharmaceutical growth rankings with an 'A' Growth Grade, while Bristol Myers Squibb lags with a 'D' grade. This comes amidst reports that the two companies are exploring a merger, which would create one of the world's largest pharmaceutical firms. A merger would …

AstraZeneca falls to third-largest UK company amid US merger talks

AstraZeneca's market value dropped by over £17bn after reports emerged of its discussions to acquire US rival Bristol Myers Squibb for nearly $400bn, causing it to lose its position as the second-largest UK company to Shell. Analysts and shareholders have expressed skepticism about the …

ZEUS delivers a bolt of pain to Novo Nordisk

Novo Nordisk's experimental cardiovascular drug, ziltivekimab, failed its phase 3 ZEUS trial, causing a 7% drop in the company's shares. The drug, an IL-6 inhibitor, did not reduce major adverse cardiovascular events despite showing expected biological activity. This setback puts pressure on Novo Nordisk …

Analysts baffled by AstraZeneca's interest in Bristol Myers Squibb

Analysts are perplexed by AstraZeneca's reported interest in acquiring Bristol-Myers Squibb, especially given AstraZeneca's strong growth and innovation. Both Jefferies and UBS, while maintaining 'buy' ratings on AstraZeneca, raised concerns about the strategic fit, potential pipeline overlap, looming patent expiries for Bristol-Myers Squibb's key …

AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb

AstraZeneca's shares fell by 7% on news of potential talks to acquire US rival Bristol Myers Squibb, a deal that could create a pharmaceutical giant worth nearly $400 billion. The acquisition would significantly expand AstraZeneca's presence in the US and mark a strategic shift …

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

Amgen (AMGN) To Report Earnings Tomorrow: Here Is What To Expect

Amgen (AMGN) is scheduled to report its earnings tomorrow. Analysts expect revenue growth of 2.4% year-on-year, a slowdown from the previous year. The company has a history of meeting or beating Wall Street's revenue estimates, and peer companies like Biogen and Moderna have recently …

AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed'

AstraZeneca's stock fell sharply after reports emerged of potential merger talks with Bristol Myers Squibb, a deal that could create a $400 billion pharmaceutical giant. Analysts expressed bewilderment over the strategic rationale, given AstraZeneca's strong growth and pipeline, while Bristol Myers faces upcoming patent …

Gilead Sciences (GILD) Q2 Earnings Report Preview: What To Look For

Gilead Sciences (GILD) is set to release its Q2 earnings this Tuesday. The market anticipates a 3.8% year-on-year revenue growth, an improvement from the previous year. Analysts have largely maintained their estimates, and the company has historically met or exceeded revenue expectations, with its …